User profiles for Joris R. de Groot
Joris R. de Groot, MD, PhD, FESCPrincipal Investigator, Academic Medical Center/University of Amsterdam Verified email at amc.uva.nl Cited by 15764 |
Implantable cardioverter-defibrillator harm in young patients with inherited arrhythmia syndromes: a systematic review and meta-analysis of inappropriate shocks and …
…, N van Dijk, J Limpens, AAM Wilde, JR de Groot - Heart Rhythm, 2016 - Elsevier
Background Implantable cardioverter-defibrillators (ICDs) are implanted with the intention to
prolong life in selected patients with inherited arrhythmia syndromes, but ICD implantation is …
prolong life in selected patients with inherited arrhythmia syndromes, but ICD implantation is …
Acute ischemia-induced gap junctional uncoupling and arrhythmogenesis
JR De Groot, R Coronel - Cardiovascular research, 2004 - academic.oup.com
Sudden cardiac death forms a major cause of mortality. Myocardial ischemia-induced ventricular
fibrillation (VF) is frequently the underlying mechanism. Ventricular arrhythmias arise in …
fibrillation (VF) is frequently the underlying mechanism. Ventricular arrhythmias arise in …
Cardiac radioablation—A systematic review
…, EMT Dieleman, AAM Wilde, PC Zei, JR de Groot… - Heart rhythm, 2020 - Elsevier
Failure of drugs and catheter ablation procedures for the treatment of ventricular arrhythmias
is still extremely relevant. Recently, stereotactic body radiotherapy has been introduced to …
is still extremely relevant. Recently, stereotactic body radiotherapy has been introduced to …
Anticoagulation with edoxaban in patients with atrial high-rate episodes
Background Device-detected atrial high-rate episodes (AHREs) are atrial arrhythmias detected
by implanted cardiac devices. AHREs resemble atrial fibrillation but are rare and brief. …
by implanted cardiac devices. AHREs resemble atrial fibrillation but are rare and brief. …
Right ventricular fibrosis and conduction delay in a patient with clinical signs of Brugada syndrome: a combined electrophysiological, genetic, histopathologic, and …
…, FJG Wilms-Schopman, AO Verkerk, JR de Groot… - Circulation, 2005 - Am Heart Assoc
Background— The mechanism of ECG changes and arrhythmogenesis in Brugada syndrome
(BS) patients is unknown. Methods and Results— A BS patient without clinically detected …
(BS) patients is unknown. Methods and Results— A BS patient without clinically detected …
Activation delay after premature stimulation in chronically diseased human myocardium relates to the architecture of interstitial fibrosis
T Kawara, R Derksen, JR de Groot, R Coronel… - Circulation, 2001 - Am Heart Assoc
Background— Progressive activation delay starting at long coupling intervals of premature
stimuli has been shown to correlate with sudden cardiac death in patients with hypertrophic …
stimuli has been shown to correlate with sudden cardiac death in patients with hypertrophic …
[HTML][HTML] Subcutaneous or transvenous defibrillator therapy
…, S Richter, MA Brouwer, JR de Groot… - … England Journal of …, 2020 - Mass Medical Soc
Background The subcutaneous implantable cardioverter–defibrillator (ICD) was designed to
avoid complications related to the transvenous ICD lead by using an entirely extrathoracic …
avoid complications related to the transvenous ICD lead by using an entirely extrathoracic …
Permanent leadless cardiac pacing: results of the LEADLESS trial
…, MA Miller, J Petru, J Simon, L Sediva, JR de Groot… - Circulation, 2014 - Am Heart Assoc
Background— Conventional cardiac pacemakers are associated with several potential short-
and long-term complications related to either the transvenous lead or subcutaneous pulse …
and long-term complications related to either the transvenous lead or subcutaneous pulse …
Sudden cardiac death in adult congenital heart disease
Z Koyak, L Harris, JR de Groot, CK Silversides… - Circulation, 2012 - Am Heart Assoc
Background— Sudden cardiac death (SCD) is a major cause of mortality in adults with congenital
heart disease (CHD). The aim of this study was to determine the adult CHD population …
heart disease (CHD). The aim of this study was to determine the adult CHD population …
Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial
…, M Kushnir, J Spinar, V Batushkin, JR De Groot… - The Lancet, 2016 - thelancet.com
Background Edoxaban, an oral factor Xa inhibitor, is non-inferior for prevention of stroke
and systemic embolism in patients with atrial fibrillation and is associated with less bleeding …
and systemic embolism in patients with atrial fibrillation and is associated with less bleeding …